NEW YORK, Sept. 17 /PRNewswire/ -- ExL Pharma is pleased to announce three Clinical Data Focused conferences which cover many of the leading issues that are impacting the pharmaceutical industry today. These events offer educational and networking opportunities for Clinical, R&D, Regulatory and Medical Affairs executives from large to small pharmaceutical, biotech, device and medical technology companies.
Listed below are details on some of the featured events and highlights from those conferences:
October 15-16, San Francisco, CA
2nd Data Monitoring Committees/DSMBs Conference -- Evaluating Trial Safety
and Efficacy through Independent Examination of Interim Clinical Data
Following a successful inaugural DMC conference in February of 2007, where over 100 industry experts gathered in Philly, ExL Pharma is proud to announce the 2nd DMC conference taking place October 15-16 in San Francisco where the industry will once again gather to evaluate trial safety and efficacy through independent examination of interim clinical data. Hear case study examples from GSK, AstraZeneca, Genentech, Amgen and join the industry's leading authorities on Drug Safety, Regulatory Affairs and Biostatistics to discuss experiences, strategies and best practices for working with DMCs and incorporating them into clinical trial designs to mitigate risk, optimize resource allocation, reassure study integrity and increase safety.
November 5-6, Arlington, VA
Pediatric Clinical Trials Conference -- Increasing Efficiency in Drug
Development by Redefining Global Regulation and Identifying Trial
Featuring roundtable discussions chaired by Dean Steven Spielberg from Dartmouth Medical School; topics lead by experts in each field include CNS/Psychiatry, Infectious Disease, Oncology, Gastroenterology, and Geographic Study Differences. Other event presentations include NICHD perspective on Best Pharmaceuticals for Children Act, changes in pediatric regulatory landscape, and industry sponsored research.
December 3-4 2007, Philadelphia, PA
Pharmacovigilance Summit 2007 -- Developing and Implementing Compliant
Strategies to Minimize the Risk of Adverse Drug Reactions and Increase
The only conference focusing on developing and implementing compliant strategies to minimize the risk of adverse drug reactions and increase drug safety. AstraZeneca, Cephalon Inc, Intermune, Sunesis Pharmaceuticals and more discuss practical crisis management and communications strategies, measuring the effectiveness of your pharmacovigilance efforts, and evaluating the effectiveness of your risk management plans and tools and more. Pre-conference workshop on The Impact of Regulation on Drug Safety.
To view our full list of upcoming conferences and webinars and details on our expert speaking faculties or to REGISTER, Log onto: http://www.exlpharma.com.
*Please mention Registration Code: ECL913 when registering
ExL Pharma, a division of ExL Events, Inc., is an emerging leader in developing innovative, educational events that serve the healthcare community and allied professionals. Behind our diverse conference portfolio, our experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality conference events designed to exceed the dynamic informational needs of the healthcare community.
|SOURCE ExL Pharma|
Copyright©2007 PR Newswire.
All rights reserved